Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy

Locoregional therapies(LRTs)of hepatocellular carcinoma(HCC)represented by ablation and TACE has become the main means for the clinical treatment of unresectable HCC.Among these,TACE is used throughout the stageⅠb toⅢb of HCC treatment.In recent years,immunotherapy led by immune checkpoint inhibitors has become a hot direction in clinical research.At the same time,targeted drugs such as Sorafenib and Apatinib have played an important role in the treatment and complementary therapy of advanced HCC,and their clinical application has been quite mature.HCC is the sixth most common malignant tumor in the world.When it comes to its treatment,different therapies have different indications,and their individual efficacies are not satisfactory,which makes the exploration of the use of combination therapy in HCC treatment become a new trend.In this paper,the status of the three therapies and the progress of their combined application are briefly reviewed.

Bibliometric and visualized analysis of the correlation between sarcopenia and chronic liver diseases from 2000 to 2023

Aims:Chronic liver disease(CLD)is increasingly recognized as a significant global public health threat,with morbidity and mortality rates remaining high.Evidence suggests that sarcopenia independently increases the risk of CLD and negatively impacts various clinical outcomes,including survival,quality of life,and the emergence of additional complications in patients with CLD.This study aimed to give a bibliometric analysis to examine the correlation between sarcopenia and CLD from a literature perspective.Methods:To understand the structure of this research field,we employed VOSviewer.The research on the correlation between long‐term liver disease and sarcopenia was obtained from the Web of Science Core Collection.VOSviewer 1.6.19.0 was utilized to examine and illustrate these publications,encompassing yearly patterns in the domain,focal points of research,significant articles,authors,journals,and organizations.Moreover,according to the results of the cluster analysis of keywords,we further searched and classified related studies to discuss.Results:This study provides a comprehensive analysis of current research trends,international collaboration models,fundamental understandings,key focus areas,and future research areas in the field of sarcopenia and CLD by reviewing publications from January 1,2000 to December 31,2023.Over the past 24 years,research in the field of sarcopenia and CLD has deepened,with a gradual increase in publications and citations from various countries,institutions,and authors.Keyword analysis of sarcopenia and CLD indicates that current research predominantly focuses on several key areas,including obesity,metabolic syndrome,hepatic steatosis,insulin resistance,inflammation,and nutrition therapy.Conclusion:This study provided a visual representation of the current research on the correlation between CLD and sarcopenia,including publication trends,global collaboration patterns,and research hotspots.This research contributes significantly by summarizing and discussing current research trends in sarcopenia and CLD,offering valuable insights into the complex relationship,and highlighting research trends,collaborations,and future directions in clinical treatment.

Global scientific trends on portal hypertension and cirrhosis in the 21st century: A bibliometric and visualized analysis

To the Editor,Cirrhosis develops histologically as regenerative nodules surrounded by fibrous bands because of chronic liver injury,resulting in portal hypertension and end‐stage liver failure.Liver cirrhosis imposes a heavy health and economic burden on many countries.In 2014,Mokdad et al.1 reported the results of the 2010 Global Burden of Disease Study(GBD).Global deaths from cirrhosis increased monotonically from just over 676,000 deaths in 1980(1.54%of global deaths)to more than 1 million deaths in 2010,or 1.95%.Portal hypertension is a group of disorders characterized by symptoms,such as hepatic encephalopathy.Cirrhosis is the main cause of portal hypertension,accounting for 80%–90%of cases.In addition,cirrhosis has fatal complications that greatly affect the quality of life of patients.